Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases
NCT03733184 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2023-11-29
Summary
Cytoreduction surgery (CRS) followed by hyperthermic intra-operative peritoneal chemotherapy (HIPEC) is a relatively new treatment for selected patients with peritoneal metastases of colorectal origin (PMCR). Data from outside of trials suggest that CRS and HIPEC improves survival compared with the current standard care (chemotherapy).
The big challenge is to do trials in this setting - as the intervention is complex, and there are wide variations in the process and recording of outcomes. If trials can confirm the findings from non-randomised studies there are an estimated 1000 to 2000 patients who may benefit from this intervention in the UK each year. The aim of this study is to develop a framework which can be used to undertake a randomised trial in patients with PMCR suitable for CRS with or without HIPEC.
The investigators will address this using the principles of the IDEAL (Idea, Development, Evaluation, Assessment \& Long term study) framework. Here, a pre-trial feasibility study will be performed between the two national peritoneal tumour treatment centres (Manchester and Basingstoke).
This study is designed as such that it will take place over the following four stages:
Stage 1. Comparing the treatment data from 100 operations from each of the two centres to identify which of the key components of the intervention differ as well as testing for differences in overall survival and recurrence free survival.
Stage 2. Identifying sources of these differences by selecting up to 25 patients and investigating the variation in the way surgeons score key aspects of the procedure
Stage 3. Development of a 'trial manual' with standardised definitions (to minimise any differences)
Stage 4. Test how well people follow the manual in practice. After this study is complete, it will be possible to use the resulting trial manual to design future randomised trials to test the most suitable clinical question.
Conditions
- Colorectal Cancer Metastatic
- Peritoneal Metastases
Interventions
- PROCEDURE
-
Cytoreduction and Heated Intraperitoneal Surgery
Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
Sponsors & Collaborators
-
The Christie NHS Foundation Trust
collaborator OTHER -
Hampshire Hospitals NHS Foundation Trust
collaborator OTHER -
University Hospital Birmingham
collaborator OTHER -
Bowel Disease Research Foundation (BDRF)
collaborator UNKNOWN -
University of Manchester
lead OTHER
Principal Investigators
-
Andrew G Renehan, PhD · The University of Manchester
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-10
- Primary Completion
- 2019-07-05
- Completion
- 2019-11-30
More Related Trials
-
Second Look Laparoscopy in Colorectal Cancer
NCT01628211 ·Status: UNKNOWN ·Phase: PHASE2
-
Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer
NCT02830139 ·Status: COMPLETED ·Phase: PHASE2
-
HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer
NCT03398512 ·Status: TERMINATED ·Phase: NA
-
Combined Anticancer Treatment of Advanced Colon Cancer
NCT01540344 ·Status: TERMINATED ·Phase: PHASE2
-
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
NCT01460745 ·Status: COMPLETED
-
Molecular Characterisation of Colorectal Cancer Peritoneal Metastases
NCT05513716 ·Status: RECRUITING
-
Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
NCT01524094 ·Status: COMPLETED ·Phase: PHASE3
-
Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases
NCT03422432 ·Status: COMPLETED ·Phase: NA
-
Patient-tailored Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases (OrganoHIPEC)
NCT06057298 ·Status: UNKNOWN ·Phase: NA
-
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
NCT02754115 ·Status: RECRUITING
-
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
NCT01189227 ·Status: TERMINATED ·Phase: PHASE3
-
Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
NCT00454519 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
NCT03073694 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
NCT04370925 ·Status: RECRUITING ·Phase: PHASE3
-
Preoperative Inflammatory Markers Predict Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Colorectal Carcinomatosis
NCT06318793 ·Status: COMPLETED
-
Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study
NCT03150628 ·Status: TERMINATED ·Phase: PHASE2
-
Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors
NCT01356706 ·Status: COMPLETED
-
Next Generation " Pre-clinical Model for Colorectal Cancer Metastases and Hepatocellular Carcinomas
NCT05384184 ·Status: COMPLETED
-
Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer
NCT04231175 ·Status: UNKNOWN ·Phase: NA
-
Late Organ Specific Adverse Effects hiPec or pElvic eXenteration
NCT04970316 ·Status: UNKNOWN
-
NeoRes Study - Preoperative Chemotherapy in Colorectal Peritoneal Disease Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT06903039 ·Status: COMPLETED
-
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
NCT03969784 ·Status: COMPLETED ·Phase: NA
-
Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis
NCT04547725 ·Status: RECRUITING ·Phase: NA
-
Adjuvant HIPEC in High Risk Colon Cancer
NCT02231086 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan
NCT01226550 ·Status: COMPLETED ·Phase: PHASE1/PHASE2